Together, these findings argue that ABT‐199 and Apatinib might interact to cause robust apoptosis and inhibition of DLBCL cells by downregulation of MAPK/ERK pathway and anti‐apoptotic BCL‐2 family proteins as well as upregulation of pro‐apoptotic BAX in DLBCL cells. Here, BCL2 is linked to diffuse large B-cell lymphoma.